Wounds - Pipeline Review, H2 2015

Date: November 30, 2015
Pages: 236
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W00F0C8433BEN
Leaflet:

Download PDF Leaflet

Wounds - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Wounds - Pipeline Review, H2 2015’, provides an overview of the Wounds’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Wounds
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Wounds
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Wounds Overview
Therapeutics Development
Pipeline Products for Wounds - Overview
Pipeline Products for Wounds - Comparative Analysis
Wounds - Therapeutics under Development by Companies
Wounds - Therapeutics under Investigation by Universities/Institutes
Wounds - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Wounds - Products under Development by Companies
Wounds - Products under Investigation by Universities/Institutes
Wounds - Companies Involved in Therapeutics Development
Advancell
Aerpio Therapeutics, Inc.
AlgiPharma AS
AndroScience Corporation
AnGes MG, Inc.
Aridis Pharmaceuticals LLC
Beech Tree Labs, Inc.
Berg LLC
Bio3 Research S.r.l
Biokine Therapeutics Ltd.
Biotec Pharmacon ASA
Birken AG
Blueberry Therapeutics Ltd
Caladrius Biosciences, Inc.
Cellphire, Inc.
CorMedix, Inc.
Destiny Pharma Limited
FibroGen, Inc.
Foresee Pharmaceuticals, LLC
GangaGen Inc.
Gene Signal International SA
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
IntelliCell BioSciences Inc.
Juventas Therapeutics, Inc.
Kuros Biosurgery AG
LegoChem Biosciences, Inc
Living Cell Technologies Limited
Molecular Design International, Inc.
NatureWise Biotech & Medicals Corporation
Novan, Inc.
Nuvo Research Inc.
Octapharma AG
Omeros Corporation
Pacific Northwest Biotechnology, LLC
ProMetic Life Sciences Inc.
Regenics AS
RXi Pharmaceuticals Corporation
Sanofi
SomaGenics Inc.
Stratatech Corporation
Sucampo Pharmaceuticals, Inc.
Symic Biomedical, Inc.
TGV-Laboratories
Thesan Pharmaceuticals, Inc.
TumorEnd, LLC
VBS Pharmaceuticals
Vida Therapeutics Inc.
Wounds - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3APO - Drug Profile
Adipose Stem Cell Therapy for Skin Wound - Drug Profile
AG-30/5C - Drug Profile
AKB-4924 - Drug Profile
ALLO-ASC - Drug Profile
ANs-31 - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile
APO-2 - Drug Profile
AR-101 - Drug Profile
Arginine Butyrate - Drug Profile
ARN-077 - Drug Profile
ASCJ-9 - Drug Profile
Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound - Drug Profile
Autologous Vascular Cells Therapy - Drug Profile
BB-1000 - Drug Profile
Biosimilar for Diabetic Wounds - Drug Profile
BKT-170 - Drug Profile
BTL-slo - Drug Profile
CAR Peptide - Drug Profile
Cell Therapy for Dermatology and Immunology - Drug Profile
Cell Therapy for Wounds - Drug Profile
CM-101 - Drug Profile
cobiprostone - Drug Profile
CR-2016 - Drug Profile
CRMD-004 - Drug Profile
CTR-2 - Drug Profile
daprodustat - Drug Profile
DB-2121 - Drug Profile
Drug for Dermatology and Infectious Diseases - Drug Profile
Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile
Drugs to Activate iRhom2 for Wound Healing and Cancer - Drug Profile
Drugs to Agonize c-Met for Wounds - Drug Profile
Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile
FG-6874 - Drug Profile
FP-009 - Drug Profile
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
GS-156 - Drug Profile
HL-156FIB - Drug Profile
Human Growth Factor - Drug Profile
hVGF - Drug Profile
JM-2 - Drug Profile
JVS-100 - Drug Profile
KL-7016 - Drug Profile
KUR-213 - Drug Profile
LCB-030110 - Drug Profile
LWnt-3a - Drug Profile
MDI-301 - Drug Profile
Mesenchymal Cells for Wound Care - Drug Profile
MG-53 - Drug Profile
MMP-26051 - Drug Profile
MMP-26052 - Drug Profile
Monoclonal Antibody Conjugated for Burns and Wounds - Drug Profile
Mul-1867 - Drug Profile
NBM-67 - Drug Profile
ND-336 - Drug Profile
NTCELL - Drug Profile
OleogelS-10 - Drug Profile
Oligomer G for Wounds And Burns - Drug Profile
Oxofoam - Drug Profile
P-128 - Drug Profile
Panaecin - Drug Profile
Pelladerm - Drug Profile
Peptide for Wounds - Drug Profile
perflenapent for wound healing - Drug Profile
Perlecan - Drug Profile
PGF - Drug Profile
plasminogen (recombinant) - Drug Profile
Polysaccharide for Wounds and Scars - Drug Profile
Protein for Diabetic Wound Healing - Drug Profile
Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile
Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
Protein to Inhibit SEB and TSST-1 for Infectious Disease, Dermatology, Respiratory Disorders and Other Diseases - Drug Profile
Recombinant Erythropoetin For Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile
Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
RNAi Oligonucleotide for Wound Healing - Drug Profile
Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles - Drug Profile
Small Molecules for Wounds and Scars - Drug Profile
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
Soluble Beta Glucan - Drug Profile
Stem Cell Therapy for Wound Healing - Drug Profile
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds - Drug Profile
Synthetic Peptides to Activate VEGF for Wound Healing and Neurodegenerative Diseases - Drug Profile
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Thrombosomes - Drug Profile
TRT-8174 - Drug Profile
ubidecarenone - Drug Profile
V-2248 - Drug Profile
Vernex - Drug Profile
VRP-017 - Drug Profile
VTI-3000 Series - Drug Profile
XF-70 - Drug Profile
Wounds - Recent Pipeline Updates
Wounds - Dormant Projects
Wounds - Discontinued Products
Wounds - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Wounds, H2 2015
Number of Products under Development for Wounds - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Number of Products under Development by Companies, H2 2015 (Contd.2)
Number of Products under Development by Companies, H2 2015 (Contd.3)
Number of Products under Development by Companies, H2 2015 (Contd.4)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd.1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Development by Companies, H2 2015 (Contd.3)
Products under Development by Companies, H2 2015 (Contd.4)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd.1)
Wounds - Pipeline by Advancell, H2 2015
Wounds - Pipeline by Aerpio Therapeutics, Inc., H2 2015
Wounds - Pipeline by AlgiPharma AS, H2 2015
Wounds - Pipeline by AndroScience Corporation, H2 2015
Wounds - Pipeline by AnGes MG, Inc., H2 2015
Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2015
Wounds - Pipeline by Beech Tree Labs, Inc., H2 2015
Wounds - Pipeline by Berg LLC, H2 2015
Wounds - Pipeline by Bio3 Research S.r.l, H2 2015
Wounds - Pipeline by Biokine Therapeutics Ltd., H2 2015
Wounds - Pipeline by Biotec Pharmacon ASA, H2 2015
Wounds - Pipeline by Birken AG, H2 2015
Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2015
Wounds - Pipeline by Caladrius Biosciences, Inc., H2 2015
Wounds - Pipeline by Cellphire, Inc., H2 2015
Wounds - Pipeline by CorMedix, Inc., H2 2015
Wounds - Pipeline by Destiny Pharma Limited, H2 2015
Wounds - Pipeline by FibroGen, Inc., H2 2015
Wounds - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
Wounds - Pipeline by GangaGen Inc., H2 2015
Wounds - Pipeline by Gene Signal International SA, H2 2015
Wounds - Pipeline by GlaxoSmithKline Plc, H2 2015
Wounds - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Wounds - Pipeline by IntelliCell BioSciences Inc., H2 2015
Wounds - Pipeline by Juventas Therapeutics, Inc., H2 2015
Wounds - Pipeline by Kuros Biosurgery AG, H2 2015
Wounds - Pipeline by LegoChem Biosciences, Inc, H2 2015
Wounds - Pipeline by Living Cell Technologies Limited, H2 2015
Wounds - Pipeline by Molecular Design International, Inc., H2 2015
Wounds - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015
Wounds - Pipeline by Novan, Inc., H2 2015
Wounds - Pipeline by Nuvo Research Inc., H2 2015
Wounds - Pipeline by Octapharma AG, H2 2015
Wounds - Pipeline by Omeros Corporation, H2 2015
Wounds - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015
Wounds - Pipeline by ProMetic Life Sciences Inc., H2 2015
Wounds - Pipeline by Regenics AS, H2 2015
Wounds - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Wounds - Pipeline by Sanofi, H2 2015
Wounds - Pipeline by SomaGenics Inc., H2 2015
Wounds - Pipeline by Stratatech Corporation, H2 2015
Wounds - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
Wounds - Pipeline by Symic Biomedical, Inc., H2 2015
Wounds - Pipeline by TGV-Laboratories, H2 2015
Wounds - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015
Wounds - Pipeline by TumorEnd, LLC, H2 2015
Wounds - Pipeline by VBS Pharmaceuticals, H2 2015
Wounds - Pipeline by Vida Therapeutics Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Wounds Therapeutics - Recent Pipeline Updates, H2 2015
Wounds - Dormant Projects, H2 2015
Wounds - Dormant Projects (Contd.1), H2 2015
Wounds - Dormant Projects (Contd.2), H2 2015
Wounds - Dormant Projects (Contd.3), H2 2015
Wounds - Dormant Projects (Contd.4), H2 2015
Wounds - Dormant Projects (Contd.5), H2 2015
Wounds - Dormant Projects (Contd.6), H2 2015
Wounds - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Wounds, H2 2015
Number of Products under Development for Wounds - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Advancell
Aerpio Therapeutics, Inc.
AlgiPharma AS
AndroScience Corporation
AnGes MG, Inc.
Aridis Pharmaceuticals LLC
Beech Tree Labs, Inc.
Berg LLC
Bio3 Research S.r.l
Biokine Therapeutics Ltd.
Biotec Pharmacon ASA
Birken AG
Blueberry Therapeutics Ltd
Caladrius Biosciences, Inc.
Cellphire, Inc.
CorMedix, Inc.
Destiny Pharma Limited
FibroGen, Inc.
Foresee Pharmaceuticals, LLC
GangaGen Inc.
Gene Signal International SA
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
IntelliCell BioSciences Inc.
Juventas Therapeutics, Inc.
Kuros Biosurgery AG
LegoChem Biosciences, Inc
Living Cell Technologies Limited
Molecular Design International, Inc.
NatureWise Biotech & Medicals Corporation
Novan, Inc.
Nuvo Research Inc.
Octapharma AG
Omeros Corporation
Pacific Northwest Biotechnology, LLC
ProMetic Life Sciences Inc.
Regenics AS
RXi Pharmaceuticals Corporation
Sanofi
SomaGenics Inc.
Stratatech Corporation
Sucampo Pharmaceuticals, Inc.
Symic Biomedical, Inc.
TGV-Laboratories
Thesan Pharmaceuticals, Inc.
TumorEnd, LLC
VBS Pharmaceuticals
Vida Therapeutics Inc.
Skip to top


Fracture - Pipeline Review, H2 2014 US$ 1,500.00 Aug, 2014 · 73 pages

Ask Your Question

Wounds - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: